Average Co-Inventor Count = 3.84
ph-index = 26
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Incyte Corporation (114 from 665 patents)
2. Incyte Holdings Corporation (46 from 147 patents)
3. Prelude Therapeutics Incorporated (7 from 18 patents)
4. Bristol-myers Squibb Compnay (1 from 3,684 patents)
5. Bristol-myers Squibb Pharma Company (1 from 234 patents)
6. Ineyte Corporation (1 from 1 patent)
7. Incyte Corportion (1 from 1 patent)
8. Prelude Therapeutics Incorporation (1 from 1 patent)
9. Prelude Therapeutis Incorporated (1 from 1 patent)
127 patents:
1. 12486277 - CDK inhibitors and their use as pharmaceuticals
2. 12448389 - BRM targeting compounds and associated methods of use
3. 12421197 - Aminopyrazine derivatives as PI3K-γ inhibitors
4. 12365668 - Aminopyrazine diol compounds as PI3K-y inhibitors
5. 12227502 - 1H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c] pyridin-7(6H)-ones as inhibitors of BET proteins
6. 12201636 - Heterocyclylamines as PI3K inhibitors
7. 12173006 - Crystalline forms of a phosphoinositide 3-kinase (PI3K) inhibitor
8. 12152033 - Use of pyrazolopyrimidine derivatives for the treatment of PI3K-δ related disorders
9. 12129262 - CDK inhibitors and their use as pharmaceuticals
10. 12030885 - Substituted imidazo[2,1-f][1,2,4]triazines as PI3K-gamma inhibitors
11. 12006320 - Heterocyclic derivatives as PI3K inhibitors
12. 11999751 - Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
13. 11952367 - Pyridine and pyridimine compounds as PI3K-gamma inhibitors
14. 11939340 - CDK inhibitors and their use as pharmaceuticals
15. 11926616 - Aminopyrazine diol compounds as PI3K-γ inhibitors